Sakar Healthcare Ltd Stock Price Today (NSE: SAKAR)
Fundamental Score
Sakar Healthcare Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sakar Healthcare Ltd share price today is ₹801.40, down 2.62% on NSE/BSE as of 17 June 2026. Sakar Healthcare Ltd (SAKAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹863.07 (Cr). The 52-week high for SAKAR share price is ₹871.30 and the 52-week low is ₹311.00. At a P/E ratio of 44.17x, SAKAR is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 6.48% and a debt-to-equity ratio of 0.24.
Sakar Healthcare Ltd Share Price Chart — NSE/BSE Historical Performance
Sakar Healthcare Ltd share price chart: 25.87% return over the past month. 52-week high ₹871.30, 52-week low ₹311.00.
Sakar Healthcare Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹848.95 | ₹848.95 | ₹800.35 | ₹834.60 | 1.34L (Cr) | |
| ₹818.00 | ₹871.30 | ₹812.10 | ₹835.70 | 4.95L (Cr) | |
| ₹796.00 | ₹823.00 | ₹783.00 | ₹796.50 | 1.55L (Cr) | |
| ₹793.00 | ₹818.00 | ₹775.05 | ₹788.25 | 1.75L (Cr) | |
| ₹815.00 | ₹835.00 | ₹781.35 | ₹786.40 | 1.14L (Cr) | |
| ₹766.85 | ₹837.75 | ₹740.00 | ₹801.00 | 2.44L (Cr) | |
| ₹790.50 | ₹805.00 | ₹749.00 | ₹761.60 | 1.36L (Cr) | |
| ₹818.00 | ₹818.80 | ₹778.00 | ₹786.75 | 1.85L (Cr) | |
| ₹766.80 | ₹829.60 | ₹760.00 | ₹809.00 | 2.92L (Cr) | |
| ₹793.15 | ₹793.15 | ₹750.50 | ₹766.80 | 1.53L (Cr) |
Sakar Healthcare Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹818.00 | ₹871.30 | ₹800.35 | ₹834.60 | +2.03% | |
| ₹628.05 | ₹837.75 | ₹520.00 | ₹796.50 | +26.82% | |
| ₹528.50 | ₹661.95 | ₹492.20 | ₹628.05 | +18.84% | |
| ₹481.00 | ₹577.95 | ₹465.00 | ₹498.45 | +3.63% | |
| ₹377.00 | ₹569.95 | ₹377.00 | ₹494.60 | +31.19% | |
| ₹409.70 | ₹439.00 | ₹361.00 | ₹391.10 | -4.54% | |
| ₹377.00 | ₹444.30 | ₹352.50 | ₹409.20 | +8.54% | |
| ₹363.80 | ₹411.80 | ₹356.25 | ₹375.45 | +3.20% | |
| ₹355.00 | ₹394.95 | ₹345.50 | ₹361.20 | +1.75% | |
| ₹329.35 | ₹378.20 | ₹321.05 | ₹358.35 | +8.81% | |
| ₹341.05 | ₹351.70 | ₹311.00 | ₹329.35 | -3.43% | |
| ₹359.80 | ₹376.00 | ₹335.00 | ₹343.85 | -4.43% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sakar Healthcare Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sakar Healthcare Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SAKAR across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (25.29%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (34.55%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (16.43% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.24)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (52.86%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (6.48%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.54%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 44.17x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (4.60% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-176.20 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Sakar Healthcare Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sakar Healthcare Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
43.9/100 | ₹801.40₹801 | ₹863.07₹863.07 | 44.17Average 44.2 Average | 6.48%Poor 6.48% Poor | 8.54%Poor 8.54% Poor | 0.24Excellent 0.2 Excellent | 12.94%Good 12.94% Good | 16.43%Excellent 16.43% Excellent | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Sakar Healthcare Ltd PE Ratio History
Historical price-to-earnings ratio for SAKAR — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹5.63 | ₹296.45 | 52.7x |
| FY 2023 | ₹6.86 | ₹400.05 | 58.3x |
| FY 2022 | ₹10.09 | ₹224.25 | 22.2x |
| FY 2021 | ₹708.58 | ₹162.65 | 0.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Sakar Healthcare Ltd Quarterly Performance
Latest quarterly metrics for SAKAR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
34.55%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-5.42%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
16.43%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
12.94%
Compounded annual net profit growth over 5 years
Sakar Healthcare Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SAKAR — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Sakar Healthcare Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Sakar Healthcare Ltd (SAKAR) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Sakar Healthcare Ltd
About SAKAR (Sakar Healthcare Ltd)
Sakar Healthcare Ltd is a dynamic pharmaceutical company committed to innovation and quality in healthcare solutions. Focused on both domestic and international markets, Sakar Heal...thcare meticulously crafts and distributes a diverse range of pharmaceutical formulations. Their expertise lies in the production of various dosage forms, including complex sterile injectables, meticulously crafted oral solids, and palatable liquid formulations. Through advanced manufacturing processes and stringent quality control measures, Sakar Healthcare ensures that each product adheres to the highest industry standards. The company consistently strives to meet the evolving healthcare needs of patients worldwide by delivering safe, effective, and affordable medicines. Sakar Healthcare demonstrates a dedication to developing cutting-edge pharmaceutical products and processes. With a team of skilled scientists and researchers, the company invests significant resources in research and development to create innovative solutions. This commitment extends to improving existing formulations and exploring new therapeutic avenues. Sakar Healthcare emphasizes compliance with regulatory guidelines and global best practices in pharmaceutical manufacturing. This commitment underscores their ambition to be a trusted partner in healthcare, providing reliable and high-quality products to enhance patient outcomes and overall well-being. Sakar Healthcare's comprehensive product portfolio spans a wide spectrum of therapeutic areas, addressing critical healthcare needs across diverse patient populations. From addressing common infections with anti-infectives to managing pain with analgesics, the company offers a range of essential medications. Furthermore, they cater to specialized treatment areas, including antihistamines for allergies, anthelmintics for parasitic infections, and anti-malarials for malaria. Sakar Healthcare aims to provide affordable access to essential medicines to improve lives and promote better health outcomes across the globe. They continuously adapt their product offerings to meet the changing needs of the healthcare landscape.
Company Details
Key Leadership
SAKAR Share Price: Frequently Asked Questions
What is the current share price of Sakar Healthcare Ltd?
Sakar Healthcare Ltd (SAKAR) trades at ₹801.40 on NSE. Market cap ₹863.07 (Cr). Educational data only.
What is the P/E ratio of Sakar Healthcare Ltd?
Sakar Healthcare Ltd has a P/E of 44.17x vs industry average 31.77x.
What is the Bull Run score for Sakar Healthcare Ltd?
Sakar Healthcare Ltd has a Bull Run score of 43.9/100 based on 25+ financial parameters.
Does Sakar Healthcare Ltd pay dividends?
Sakar Healthcare Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Sakar Healthcare Ltd?
Sakar Healthcare Ltd has ROE of 6.48%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sakar Healthcare Ltd?
Sakar Healthcare Ltd has debt-to-equity of 0.24.
Is Sakar Healthcare Ltd a good investment?
Bull Run gives Sakar Healthcare Ltd a score of 43.9/100. This is not investment advice — consult a SEBI-registered advisor.